Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

186.47 -0.88 (-0.47%)

Streaming Delayed Price Updated: 12:04 PM EST, Feb 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

2 Soaring Stocks Wth More Upside Potential ↗

June 05, 2025

Via The Motley Fool

Axsome Therapeutics to Participate in Upcoming Investor Conferences

May 29, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

May 28, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Why Is Teva Stock Trading Higher On Tuesday? ↗

May 27, 2025

Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.

Via Benzinga

Earnings Scheduled For May 5, 2025 ↗

May 05, 2025

Via Benzinga

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

May 27, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

3 High-Flying Stocks That Could Soar Even More ↗

May 24, 2025

Via The Motley Fool

Expert Outlook: Axsome Therapeutics Through The Eyes Of 16 Analysts ↗

May 22, 2025

Via Benzinga

Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis ↗

May 14, 2025

Via The Motley Fool

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

May 13, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years ↗

May 12, 2025

Via The Motley Fool

3 Monster Stocks in the Making ↗

May 11, 2025

Via The Motley Fool

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1 ↗

May 05, 2025

Axsome beat Q1 expectations with $121.5 million in revenue and strong Auvelity sales as it prepares Symbravo's U.S. launch and advances key drug programs.

Via Benzinga

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 05, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

May 01, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings) ↗

April 29, 2025

Via Benzinga

Axsome Therapeutics to Participate in Upcoming Investor Conferences

April 22, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT)

April 14, 2025

From Grabar Law Office

Via GlobeNewswire

Attention Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office Investigates

April 11, 2025

From Grabar Law Office

Via GlobeNewswire

ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions

April 08, 2025

From Grabar Law Office

Via GlobeNewswire

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

April 08, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

April 07, 2025

Via Benzinga

April 07, 2025

From Grabar Law Office

Via GlobeNewswire

SECURITIES FRAUD CLASS ACTIONS SURVIVE MOTIONS TO DISMISS: Grabar Law Office Investigates Claims on Behalf of Shareholders of Arqit Quantum Inc. (NASDAQ: ARQQ); Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); and Maison Solutions

April 04, 2025

From Grabar Law Office

Via GlobeNewswire

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

April 04, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Stocks Edge Higher Despite Trade, Economic Jitters ↗

April 01, 2025

Stocks are modestly higher Tuesday afternoon, as Wall Street shakes off a sluggish open amid a new wave of economic data.

Via Talk Markets

Topics Stocks / Equities

Why Shares of Axsome Therapeutics Slumped Today ↗

April 01, 2025

Via The Motley Fool

Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week ↗

April 01, 2025

The company posted mixed results for its depression treatment, noting it appears to work in a smaller patient group.

Via Investor's Business Daily

Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder ↗

April 01, 2025

Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients supports plans for a new study in 2025.

Via Benzinga

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

April 01, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.